Posted by Michael Wonder on 24 Nov 2021
FDA approves first treatment for common type of post-transplant infection that is resistant to other drugs
23 November 2021 - Today, the U.S. FDA approved Livtencity (maribavir) as the first drug for treating adults and paediatric patients (12 years of age and older and weighing at least 35 kilograms) with post-transplant cytomegalovirus infection/disease that does not respond (with or without genetic mutations that cause resistance) to available antiviral treatment for cytomegalovirus.
Livtencity works by preventing the activity of human cytomegalovirus enzyme pUL97, thus blocking virus replication.
